Abstract Objective: We evaluated the incidence of aorto-oesophageal (AEF) and aortobronchial (ABF) fistulae after thoracic endovascular aortic repair (TEVAR), and investigated their clinical features, determinants, therapeutic options and results. Methods: We conducted a voluntary national survey among Italian universities and hospital centres with a thoracic endovascular programme. Results: Thirty-nine centres were contacted, and 17 participated. Of the patients who underwent TEVAR between 1998 and 2008, 19/1113 (1.7%) developed AEF/ABF. Among indications to TEVAR, aortic pseudo-aneurysm was associated with the development of late AEF/ABF (P Z 0.009). Further, emergent and complicated procedures resulted in increased risk of AEF/ABF (P Z 0.008 and P < 0.001, respectively). Eight patients were treated conservatively, all of whom died within 30 days. Eleven patients underwent AEF/ABF surgical treatment, with a perioperative mortality of 64% (7/11). At a mean follow-up of 17.7 AE 12.5 months, overall survival was 16% (3/19). Conclusions: The incidence of AEF and ABF following TEVAR is not negligible, and is comparable to that following open repair. This finding warrants an ad hoc long-term follow-up after TEVAR, particularly in patients submitted to emergent and complicated procedures. Both surgical and endovascular treatment of AEF/ABF are associated with high mortality. However, conservative treatment does not appear to be a viable option. ª
Aorto-oesophageal (AEF) and aortobronchial (ABF) fistulae are uncommon and highly fatal conditions that occur most frequently secondary to thoracic trauma, aortic aneurysms, ruptured penetrating aortic ulcers, oesophageal or bronchogenic malignancies and thoracic surgery. 1 In particular, the incidence of AEF/ABF as a complication of open repair of the thoracic and thoraco-abdominal aorta ranges from 0.5%e1.7%. 2, 3 Since its introduction in the early 1990s, 4 thoracic endovascular aortic repair (TEVAR) has become the most important therapeutic alternative for high-risk patients with thoracic aortic disease. With growing numbers of interventional thoracic aortic procedures and increasing follow-up periods, late complications of TEVAR have become increasingly evident over time, including postprocedural AEF and ABF.
5e8 However, relatively little is known about these sequelae because of their rarity, the fairly recent clinical introduction of endovascular techniques and the lack of multicentre reports.
The objective of this study was to evaluate the incidence of post-TEVAR AEF/ABF, investigate clinical features and determinants and assess the efficacy of therapeutic measures by means of a national survey conducted in Italy.
Methods
We conducted a cross-sectional survey on a voluntary basis among Italian universities and hospital centres with a thoracic endovascular programme. A text documentbased survey developed by us was distributed in November 2007 by e-mail to the medical directors of Italian departments of vascular surgery or cardiothoracic surgery known to have experience with thoracic aorta stent grafting. Centres that performed TEVAR on a regular basis, even if they lacked direct experience with AEF/ABF treatment, were invited to participate. Accompanying the questionnaire was a letter explaining the aims of the study and the compiling modalities. Each centre that failed to respond was contacted by telephone or solicited by e-mail. The survey ended in December 2008. Participating centres (listed in Table 1 ) were requested to provide data from patients that underwent TEVAR for noninfectious aortic disease between 1998 and 2008, and data from patients presenting a post-TEVAR AEF and/or ABF in the same period. In addition, data regarding results of endovascular repair of an established AEF or ABF were collected within the same survey. These data, however, pertain to different patients with different pathologies, and were reported in a separate publication. 39 Patient names or identifiers were not requested or provided.
Demographics and preoperative risk factors, including coronary artery disease, pulmonary disease and renal failure were defined as previously reported. 9 The anatomic location of the proximal landing zone was defined according to the 'aortic arch map'proposed by Ishimaru (0e4). 10 The results of TEVAR were described according to the reporting standards for endovascular aortic aneurysm repair. 11 Renal dysfunction was defined as a rise in serum creatinine exceeding the baseline value by 30% and surpassing an absolute level of 2.0 mg dl À1 . 12 Myocardial infarction was suggested by electrocardiographic changes and confirmed by elevation of cardiac enzymes, regardless of symptoms. Respiratory failure was defined as ventilator dependence lasting >72 h, the need for postoperative reintubation, clinical data or culture confirmation of pneumonia or the need for tracheostomy. 12 Patients were followed-up according to the protocol of each institution; in all cases, this included thoracic contrast-enhanced computed tomography (CT) or magnetic resonance (MR) imaging and an outpatient clinical evaluation.
Patients who developed AEF/ABF following TEVAR were compared with the global cohort of patients who underwent TEVAR in terms of preoperative and intra-operative variables of interest, using the Fisher exact test or c 2 test for categorical data, and the unpaired t-test or Manne Whitney test for continuous data, as appropriate. All analyses were run using SAS 8.02 software (SAS Institute Inc., Cary, NC, USA).
Results
In general, 17 out of the 39 contacted centres, including that of the authors, provided patient data ( Indications for TEVAR (Table 3) included atherosclerotic aortic aneurysm, penetrating ulcer, intramural haematoma, acute and chronic dissection, traumatic injury, coarctation and anastomotic pseudo-aneurysm following previous aortic open repair. Only anastomotic pseudoaneurysm was significantly associated with AEF/ABF development (16% vs. 2%; P Z 0.009). In addition, emergently performed procedures were associated with an increased risk of AEF/ABF (37% vs. 13%; P Z 0.008; Table 3 ). Six types of commercially available stent grafts from five different manufacturers were employed ( Table 4 ). The mean stent graft proximal diameter was 37.9 AE 5.3 mm. A mean number of 1.4 AE 0.5 devices per patient were implanted. The mean aortic length to be covered was 171.8 AE 61.1 mm. An intended stent graft oversizing at the proximal landing zone of 10e19% was used in 11 cases (58%), 20% in six cases (32%) and 21e30% in two cases (10%).
Cerebrospinal fluid drainage was instituted in three patients (16%). The mean duration of the procedure was 160 AE 139 min, and the mean estimated blood loss 534 AE 516 ml. Ballooning was performed in 12 cases (63%). Concomitant supra-aortic vessel debranching was performed in three cases (16%).
Primary technical success was obtained in 17/19 cases (Table 5) . One patient underwent implantation of a proximal additional cuff to treat a type I endoleak. Perioperative complications occurred in eight patients (42%), including renal dysfunction in five cases, respiratory failure in five cases and stroke in one case. Compared to the global cohort of patients who underwent TEVAR, the occurrence of perioperative complications was significantly associated with late AEF/ABF development (42% vs. 12%; P < 0.001), particularly in cases with postoperative renal dysfunction (P < 0.001) and respiratory failure (P Z 0.001).
The mean interval between TEVAR and fistula detection was 10.9 AE 15.4 months. The fistula involved the oesophagus in 13 cases (68%) and the left bronchial tree in one case (5%); there was concomitant broncho-oesophageal involvement in five cases (26%). The symptoms at presentation and the diagnostic modalities that disclosed AEF/ABF are reported in Table 6 . In one patient who died of sudden (Table 7) . Treatment included aortic surgical repair in two patients, with associated oesophageal reconstruction in one of them. Aortic reendografting was performed in three patients, with associated oesophageal reconstruction in one of them. Six patients underwent oesophageal and/or bronchial repair alone (Fig. 1) . Perioperative mortality was 64% (7/11). Of the survivors, one patient died 6 months after the operation due to unrelated causes. Another patient underwent successful multiple re-interventions, including total oesophagectomy and thoracic aortic reconstruction under deep hypothermic circulatory arrest. At a mean follow-up of 17.7 AE 12.5 months, the overall survival was 16% (3/19).
Discussion
First described by Dubrueil in 1818 and by Girardet in 1914, 16, 17 AEF and ABF are well-known rare causes of massive gastrointestinal and respiratory bleeding that are associated with high morbidity and mortality. Although the most common cause of fistulisation is the erosion of a thoracic aortic aneurysm, 18 secondary AEF and ABF are also known to develop late after thoracic aortic surgery in up to 1.7% of patients.
2,3 Our survey revealed that the incidence of post-TEVAR AEF and ABF is comparable to the incidence after open repair surgery; therefore, in this respect, endovascular treatment of the thoracic aorta does not appear to provide any advantage over conventional repair.
We found that pseudo-aneurysm as an indication for TEVAR represents a significant risk factor for late fistulisation. Compression of the oesophagus or the airways by the pseudo-aneurysm may result in a local inflammatory response, formation of stable adhesions and tissue necrosis, leading to erosion and final fistulisation. Although endovascular treatment has been proposed as a less-invasive and safe alternative to open surgery for repair of thoracic pseudo-aneurysms, 19, 20 our data show that TEVAR may lead to long-term serious complications in this setting.
Endoluminal repair of thoracic aortic disease requiring emergent or urgent treatment has yielded encouraging early results with low morbidity and mortality rates compared with open surgery. 21 However, our survey revealed that emergent TEVAR is associated with an increased risk of late AEF/ABF development, indicating a need for caution after these procedures. The mechanisms underlying this finding are unclear, but we speculate that aortic lesions that require emergent repair often entail extravasation of blood and periaortic haematoma, with increased local inflammatory response and compression of surrounding organs. These factors, which are not ameliorated by aortic stent grafting, may play a role in late fistulisation. 22 We also found that the occurrence of perioperative complications after TEVAR, particularly renal dysfunction and respiratory failure, were significant predictors of AEF/ ABF development. A closer follow-up of these patients may help to recognise AEF/ABF early, although there is no evidence that early detection should improve the prognosis.
Post-TEVAR fistulae have been reported to occur as a result of endoleak into the residual aneurysm sac, erosion of the stent graft through the aorta and ischaemic necrosis of the oesophageal/bronchial wall resulting from stent coverage of their feeding arteries. 7, 8, 23 However, our survey found that the rate of residual type I endoleak in patients presenting an AEF/ABF was comparable to that of the global cohort; only one patient had an endoleak at the time of AEF detection. This result could be due to the low incidence rate of endoleaks (type II error); therefore, we believe that patients presenting endoleak should be always closely followed up.
Different thoracic stent grafts were used in the patients who developed AEF/ABF. Specific device characteristics, the number of stent grafts used and the length of the covered aorta were not significantly associated with AEF/ABF development. We found that 42% of patients presenting late AEF/ABF had a proximal oversizing of 20% or more, regardless of the manufacturer's recommendations. Although this cannot be appointed as a risk factor because the proportion of oversized grafts in the global cohort of TEVAR patients is unknown, excessive stent graft oversizing has been previously shown to result in long-term deterioration of the arterial wall, stent-graft migration and aortic aneurysm enlargement, 24, 25 and should be taken into account as a possible additional mechanism of fistulisation. 26, 27 AEF/ABF were observed at different time intervals during the follow-up, and therefore their occurrence appears to be unpredictable. The most common presenting symptom was upper gastrointestinal or respiratory bleeding, followed by chronic fever. CT scan was the first imaging study performed in most of the cases, because it is easy to carry out in emergency conditions. Although CT scans rarely detect fistulous tracts, suggestive signs of AEF/ABF are present in most patients, including air bubbles into the thrombus, periaortic fluid collection, oesophageal or bronchial wall thickening and lung consolidation. 19, 28, 29 Endoscopy is the most sensitive and specific method for the diagnosis of AEF/ABF, 30 but often requires sedation and entails the risk of dislodging clots during the progress of the endoscope, which can cause fatal bleeding. 31 Mortality after surgery for thoracic aortic fistulae has been shown to reach 61% in cases of primary etiology 32 and 78% in cases of secondary fistulae. 33 Conventional treatment includes surgical aortic repair, which is most commonly performed via a left posterolateral thoracotomy. Recently, TEVAR was proposed as an alternative strategy for the surgical management of AEF and ABF. 34, 35 Although less-invasive, this technique presents important limitations, mainly the high risk of graft contamination. Several Figure 1 Aortoesophageal fistula following TEVAR. A) Preoperative CT scan demonstrating air bubbles in the thrombus (arrows). B) Intra-operative photograph during surgical conversion shows thoracic stent-graft removal, and aortic in situ reconstruction with a silver-coated prosthetic graft.
authors have proposed a variety of combinations of TEVAR with surgical aortic repair, oesophageal stent grafting, tracheobronchial or oesophageal reconstruction, mediastinal drainage or even endoscopic use of fibrin glue at the level of the fistula. 36e38 The long-term efficacy and safety of these techniques, however, has yet to be determined.
The operative mortality of post-TEVAR AEF/ABF repair was 63.6% in our series. No significant differences in terms of either early or late mortality were observed between AEF and ABF. Although, in our study, mortality appeared to be independent of the surgical technique used, we cannot make general recommendations for the surgical treatment of AEF and ABF due to the small number of cases. Consistent with previous findings, according to our survey, both AEF and ABF were invariably fatal if left untreated.
In conclusion, although rare, AEF and ABF are considerable late sequelae of TEVAR, particularly in patients who underwent emergent procedures or who experienced perioperative complications. Both surgical and endovascular treatment are associated with high mortality, but conservative treatment is not a viable option. Further studies are needed to assess the optimal management of these complications.
